Entrada Therapeutics, Inc. (NASDAQ: TRDA) is a Healthcare company (Biotechnology) with a market capitalization of $194M. The Maz Rating grades it against the other companies in its sector.
Entrada Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.96, Entrada Therapeutics, Inc. trades at 53.3x sales and 1.2x book value. Over the last twelve months it generated about $4M of revenue and a net loss of $138M. It runs a gross margin of 57.5%, an operating margin of -4303.8% and a net margin of -4058.0%. It shows return on equity of -64.0%, return on invested capital of -69.7% and a free cash flow yield of -70.2%. On the balance sheet: a debt-to-equity ratio of 0.24 and a current ratio of 7.85. Over the past 52 weeks the share price ranged from $4.11 to $16.45, with a beta of -0.24.
Entrada Therapeutics, Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 4 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Entrada Therapeutics, Inc. (TRDA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 76.9% / 30% · Interest income / Revenue 218.1% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 76.9% / 33% · Receivables / Mkt Cap (36m) 0.33% / 49% · Interest income / Revenue 218.1% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 76.9% / 33.33% · Receivables / Mkt Cap (24m) 0.33% / 33.33% · Interest income / Revenue 218.1% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 75.6% / 33.33% · Receivables / Avg Assets (4Q) 0.40% / 33.33% · Interest income / Revenue 218.1% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 72.3% / 33.33% · (Cash+Recv) / Total Assets 72.6% / 33.33% · Interest income / Revenue 218.1% / 5% | Fail |
No. As of September 2026, Entrada Therapeutics, Inc. (TRDA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Entrada Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 218.1% of each dividend: Entrada Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.